

Cordis Launches MYNX CONTROL Vascular Closure Device

Dublin, Ohio, November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S. launch of MYNX CONTROL™ Vascular Closure Device (VCD). MYNX CONTROL™ VCD integrates active extravascular sealing and resorbability properties with a next-generation delivery system to maximize predictability, safety, and ease of use in sealing 5-7F femoral arterial access sites. Vascular closure devices reduce time to hemostasis and ambulation in patients who have undergone diagnostic or interventional procedures.¹

MYNX CONTROL™ VCD features a next-generation deployment system that is designed for predictable deployment and ease of use. It will be available in 5F as well as 6/7F sizes. Highlights of this new system include:

- sheath catch that is compatible with the procedural sheath
- tension indicator that provides visual confirmation of device position for proper sealant deployment
- ergonomic handle with a 2-button deployment design to simplify procedural steps

Leveraging the proven MYNXGRIP® VCD technology, which has been used in over two million interventional cases worldwide, the MYNX CONTROL™ VCD utilizes a dual-mode active sealing mechanism. This allows the sealant to interlock with the contours of the arterial wall, expanding to fill the tissue tract and create a matrix structure for clot formation. With all closure components resorbing within 30 days, nothing is left behind. The MYNX® VCD technology has been clinically proven to reduce surgical complications, expedite recovery, shorten hospital stays, and increase patient comfort.¹⁻⁶

“The notion of secure extravascular closure with nothing left behind is very appealing for a number of reasons,” said Ali Almedhychy, MD, global medical director at Cordis. “In addition to the clinical benefits of undisrupted flow in the artery, MYNX CONTROL™ VCD minimizes technique-related issues and emphasizes simplicity and reproducibility.”

“MYNX CONTROL™ VCD reinforces Cordis leadership in global vascular closure innovation,” commented Patrick Holt, president at Cordis. “By adding new access, diagnostic, interventional and closure products to our portfolio, we continue to make significant patient-centric contributions to the delivery of healthcare.”

As a global leader in the treatment of cardiovascular disease, Cordis continues to grow its product portfolio, including via recent strategic alliances, bringing customers the EluNIR® Drug-Eluting Stent (DES), TRYTON Side Branch Stent, and MOZEC™ PTCA Balloon Dilatation Catheters.

About Cardinal Health

Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically proven medical products, pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. To help combat prescription drug abuse, the company and its education partners created Generation Rx, a national drug education and awareness program. Backed by nearly 100 years of experience, with approximately 50,000 employees in nearly 46 countries, Cardinal Health ranks #14 on the *Fortune* 500. For more information, visit cardinalhealth.com, follow @CardinalHealth on Twitter, @cardinalhealthwings on Facebook and connect on LinkedIn at [linkedin.com/ company/cardinal-health](https://www.linkedin.com/company/cardinal-health).

1. MYNX Control Vascular Closure Device Instructions for Use.

2. Pruski MJ Jr, Blachut AM, Konkolewska M, et al. MynxGrip for closure of antegrade puncture after peripheral interventions with same-day discharge. *Vasc Endovasc Surg*. 2017 Feb;51(2):67-71.

3. Baker NC, Escarcega RO, Lipinski MJ, et al. Active versus passive anchoring vascular closure devices following percutaneous coronary intervention: a safety and efficacy comparative analysis. *J Interv Cardiol*. 2016 Feb; 29(1): 108-112.

4. Hutchings D, Hayat A, Karunakaran A, Malik N. Success, safety, and efficacy of the Mynx femoral closure device in a real-world cohort: single-center experience. *J Invasive Cardiol*. 2016 Mar;28(3): 104-108.
 5. Noor S, Meyers S, Curl R. Successful reduction of surgeries secondary to arterial access site complications: a retrospective review at a single center with an extravascular closure device. *Vasc Endovascular Surg*. 2010 Jul;44(5):345-349.
 6. Fargen KM, Hoh BL, Mocco J. A prospective randomized single-blind trial of patient comfort following vessel closure: extravascular synthetic sealant closure provides less pain than a self-tightening suture vascular compression device. *J NeuroInterv Surg*. 2011 Sep; 3(3): 219-223.
-

<https://newsroom.cardinalhealth.com/MynxControl>